Corcept Therapeutics Share Price Today
(NASDAQ: CORT)

Name: Corcept Therapeutics Share Price Today (NASDAQ: CORT) - Corcept Therapeutics Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Corcept Therapeutics share price is $61.53 & ₹5,328.37 as on 30 Jan 2025, 2.30 'hrs' IST

$61.53

▲

0.87

(1.43%)

Market is closed - opens 8 PM, 30 Jan 2025

View live Corcept Therapeutics share price in Dollar and Rupees. Guide to invest in Corcept Therapeutics stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Corcept Therapeutics, along with analyst recommendations, forecasts, and comprehensive financials.

Corcept Therapeutics share price movements

Today's Low: $60.10
Today's High: $61.81
$61.53
2.32%
Downside
Day's Volatility :2.77%
Upside
0.45%
52 Weeks Low: $20.84
52 Weeks High: $62.98
$61.53
66.13%
Downside
52 Weeks Volatility :66.91%
Upside
2.3%

Corcept Therapeutics (CORT) Returns

Period	Corcept Therapeutics Inc	Sector (Health Care)	Index (Russel 2000)
3 Months	25.65%	-1.7%	0.0%
6 Months	62.18%	-3.0%	0.0%
1 Year	191.61%	3.6%	0.0%
3 Years	227.81%	11.6%	-10.1%

Corcept Therapeutics (CORT) Key Statistics

in dollars & INR

Previous Close	$60.66
Open	$60.39
Today's High	$61.8111
Today's Low	$60.1
Market Capitalization	$6.4B
Today's Volume	$420.6K
52 Week High	$62.98
52 Week Low	$20.84
Revenue TTM	$628.6M
EBITDA	$144.1M
Earnings Per Share (EPS)	$1.26
PE Ratio	48.83
Profit Margin	22.56%
Quarterly Earnings Growth YOY	0.46%
Return On Equity TTM	25.77%

How to invest in Corcept Therapeutics Stock (CORT) from India?

It is very easy for Indian residents to invest directly in Corcept Therapeutics from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Corcept Therapeutics stock in both Indian Rupees (INR) and US Dollars (USD). Search for Corcept Therapeutics or CORT on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Corcept Therapeutics or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Corcept Therapeutics shares which would translate to 0.014 fractional shares of Corcept Therapeutics as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Corcept Therapeutics, in just a few clicks!

Returns in Corcept Therapeutics (CORT) for Indian investors in Rupees

The Corcept Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Corcept Therapeutics investment value today

Current value as on today

₹2,95,909

Returns

₹1,95,909

(+195.91%)

Returns from Corcept Therapeutics Stock

₹1,91,611 (+191.61%)

Dollar Returns

₹4,297 (+4.3%)

Indian investors sentiment towards Corcept Therapeutics (CORT)

-9.3%

Period: Dec 30, 2025 to Jan 29, 2025. Change in 30 Days versus previous period

Investment in Corcept Therapeutics Shares from India has dropped by -9.3% over the past 30 days, indicating reduced transactional activity.

-44%

Period: Dec 30, 2025 to Jan 29, 2025. Change in 30 Days versus previous period

Search interest for Corcept Therapeutics Stock from India on INDmoney has decreased by -44% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Corcept Therapeutics

BlackRock Inc
15.32%
Vanguard Group Inc
9.55%
Ingalls & Snyder LLC
7.89%
Renaissance Technologies Corp
6.21%
Parallel Advisors, LLC
3.64%
State Street Corp
3.36%

Analyst Recommendation on Corcept Therapeutics

Buy

90%Buy

9%Hold

0%Sell

Based on 11 Wall street analysts offering stock ratings for Corcept Therapeutics(by analysts ranked 0 to 5 stars)

Based on 11 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Corcept Therapeutics Stock (CORT)

What analysts predicted

Upside of 21.73%

Target:

$74.90

Current:

$61.53

Insights on Corcept Therapeutics Stock (Ticker Symbol: CORT)

Price Movement
In the last 1 month, CORT stock has moved up by 21.0%
Increasing Revenue
Revenue is up for the last 9 quarters, 101.72M → 182.54M (in $), with an average increase of 7.0% per quarter
Increasing Net Profit
Netprofit is up for the last 3 quarters, 27.76M → 46.69M (in $), with an average increase of 22.9% per quarter

CORT Corcept Therapeutics Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$251.2M	↑ 57.82%
Net Income	$75.4M	↓ 41.6%
Net Profit Margin	30.01%	↓ 51.1%

	FY19	Y/Y Change
Revenue	$306.5M	↑ 21.99%
Net Income	$94.2M	↑ 24.89%
Net Profit Margin	30.73%	↑ 0.72%

	FY20	Y/Y Change
Revenue	$353.9M	↑ 15.46%
Net Income	$106.0M	↑ 12.56%
Net Profit Margin	29.96%	↓ 0.77%

	FY21	Y/Y Change
Revenue	$366.0M	↑ 3.42%
Net Income	$112.5M	↑ 6.13%
Net Profit Margin	30.74%	↑ 0.78%

	FY22	Y/Y Change
Revenue	$401.9M	↑ 9.8%
Net Income	$101.4M	↓ 9.86%
Net Profit Margin	25.24%	↓ 5.5%

	FY23	Y/Y Change
Revenue	$482.4M	↑ 20.04%
Net Income	$106.1M	↑ 4.66%
Net Profit Margin	22.0%	↓ 3.24%

	Q2 FY23	Q/Q Change
Revenue	$117.7M	↑ 11.42%
Net Income	$27.5M	↑ 73.36%
Net Profit Margin	23.39%	↑ 8.36%

	Q3 FY23	Q/Q Change
Revenue	$123.6M	↑ 5.0%
Net Income	$31.4M	↑ 13.99%
Net Profit Margin	25.39%	↑ 2.0%

	Q4 FY23	Q/Q Change
Revenue	$135.4M	↑ 9.55%
Net Income	$31.4M	↓ 0.07%
Net Profit Margin	23.16%	↓ 2.23%

	Q1 FY24	Q/Q Change
Revenue	$146.8M	↑ 8.42%
Net Income	$27.8M	↓ 11.46%
Net Profit Margin	18.91%	↓ 4.25%

	Q2 FY24	Q/Q Change
Revenue	$163.8M	↑ 11.57%
Net Income	$35.5M	↑ 27.83%
Net Profit Margin	21.67%	↑ 2.76%

	Q3 FY24	Q/Q Change
Revenue	$182.5M	↑ 11.45%
Net Income	$46.7M	↑ 31.57%
Net Profit Margin	25.58%	↑ 3.91%

	FY18	Y/Y Change
Profit	$246.0M	↑ 58.07%

	FY19	Y/Y Change
Profit	$301.0M	↑ 22.33%

	FY20	Y/Y Change
Profit	$348.3M	↑ 15.72%

	FY21	Y/Y Change
Profit	$360.7M	↑ 3.56%

	FY22	Y/Y Change
Profit	$396.5M	↑ 9.92%

	FY23	Y/Y Change
Profit	$475.9M	↑ 20.03%

	Q2 FY23	Q/Q Change
Profit	$116.1M	↑ 11.39%

	Q3 FY23	Q/Q Change
Profit	$122.0M	↑ 5.01%

	Q4 FY23	Q/Q Change
Profit	$133.5M	↑ 9.49%

	Q1 FY24	Q/Q Change
Profit	$144.3M	↑ 8.05%

	Q2 FY24	Q/Q Change
Profit	$161.3M	↑ 11.78%

	Q3 FY24	Q/Q Change
Profit	$179.7M	↑ 11.41%

	FY18	Y/Y Change
Operating Cash Flow	$115.7M	↑ 89.82%
Investing Cash Flow	$-90.8M	↑ 23.57%
Financing Cash Flow	$-14.3M	↑ 80.25%

	FY19	Y/Y Change
Operating Cash Flow	$136.1M	↑ 17.68%
Investing Cash Flow	$-117.8M	↑ 29.81%
Financing Cash Flow	$-28.6M	↑ 99.83%

	FY20	Y/Y Change
Operating Cash Flow	$152.0M	↑ 11.65%
Investing Cash Flow	$-119.3M	↑ 1.22%
Financing Cash Flow	$12.2M	↓ 142.64%

	FY21	Y/Y Change
Operating Cash Flow	$167.9M	↑ 10.48%
Investing Cash Flow	$136.1M	↓ 214.14%
Financing Cash Flow	$-302.6M	↓ 2577.41%

	FY22	Y/Y Change
Operating Cash Flow	$120.3M	↓ 28.33%
Investing Cash Flow	$-114.3M	↓ 183.99%
Financing Cash Flow	$-17.3M	↓ 94.29%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$42.3M	↑ 62.91%
Investing Cash Flow	$-24.1M	↓ 111.61%
Financing Cash Flow	$-145.8M	↓ 80627.07%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$52.9M	↑ 25.12%
Investing Cash Flow	$-109.6M	↑ 354.7%
Financing Cash Flow	$-3.9M	↓ 97.31%

Corcept Therapeutics Technicals Summary

Sell

Neutral

Buy

Corcept Therapeutics is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Corcept Therapeutics (CORT) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Corcept Therapeutics Inc	22.11%	62.18%	191.61%	227.81%	381.83%
Biontech Se	6.33%	50.17%	27.48%	-29.59%	300.26%
Regeneron Pharmaceuticals, Inc.	-3.52%	-37.13%	-27.1%	12.93%	101.47%
Vertex Pharmaceuticals Incorporated	9.64%	-12.71%	1.88%	81.66%	91.54%
Alnylam Pharmaceuticals, Inc.	16.44%	2.0%	58.46%	99.12%	138.96%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Corcept Therapeutics Inc	48.83	48.83	0.61	1.35	0.26	0.13	NA	6.1
Biontech Se	160.8	NA	0.04	-3.32	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	16.98	16.98	1.06	45.11	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.16	0.48	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Corcept Therapeutics Inc	Buy	$6.4B	381.83%	48.83	22.56%
Biontech Se	Buy	$29.8B	300.26%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.4B	101.47%	16.98	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$113.5B	91.54%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$36.0B	138.96%	NA	-15.86%

About Corcept Therapeutics

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing's syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Organization	Corcept Therapeutics
Employees	352
CEO	Dr. Joseph K. Belanoff M.D.
Industry	Health Technology

Management People of Corcept Therapeutics

Name	Title
Dr. Joseph K. Belanoff M.D.	Co-Founder, President, CEO & Director
Mr. Atabak Mokari	CFO & Treasurer
Mr. Sean Maduck	President of Endocrinology
Dr. William Guyer Pharm.D.	Chief Development Officer
Mr. Gary Charles Robb J.D.	Chief Business Officer & Secretary
Mr. Joseph Douglas Lyon	Chief Accounting & Technology Officer
Dr. Hazel Hunt Ph.D.	Chief Scientific Officer
Ms. Amy Flood	Chief Human Resources & Communications Officer
Ms. Monica Tellado	President of Emerging Markets
Mr. Roberto W. Vieira	President of Oncology

Important FAQs about investing in CORT Stock from India :

What is Corcept Therapeutics share price today?

Corcept Therapeutics share price today stands at $61.53, Open: $60.39 ; Previous Close: $60.66 ; High: $61.81 ; Low: $60.10 ; 52 Week High: $62.98 ; 52 Week Low: $20.84.

The stock opens at $60.39, after a previous close of $60.66. The stock reached a daily high of $61.81 and a low of $60.10, with a 52-week high of $62.98 and a 52-week low of $20.84.

Can Indians buy Corcept Therapeutics shares?

Yes, Indians can invest in the Corcept Therapeutics (CORT) from India.

With INDmoney, you can buy Corcept Therapeutics at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Corcept Therapeutics at zero transaction cost.

How can I buy Corcept Therapeutics shares from India?

It is very easy to buy Corcept Therapeutics from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Corcept Therapeutics (CORT) be purchased?

Yes, you can buy fractional shares of Corcept Therapeutics with INDmoney app.

What are the documents required to start investing in Corcept Therapeutics stocks?

To start investing in Corcept Therapeutics, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.